DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for papillary carcinoma — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePapillary carcinoma maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for papillary carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
hexokinase 1 (HK1) — HK1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet g6pdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1CZA · 1.9 Å · ligand 6-O-phosphono-alpha-D-glucopyranose (G6P). Experimental structure, not a prediction.
What the evidence adds up to
Papillary carcinoma can arise in the thyroid, breast, larynx, and sinuses. A 1996 case report describes a papillary thyroid carcinoma that metastasised to the sphenoid-ethmoid sinuses and skull base; the tumour contained areas of insular and anaplastic degeneration with strong positive staining for p53 oncogene, and management included surgery, radioactive iodine, and external beam radiation. A 2018 case from Brazil reports laryngeal papillary carcinoma as a rare entity, though on histopathological study the lesion was classified as papillary squamous cell carcinoma.
A 2022 study of 42 patients with 45 papillary breast carcinoma lesions found that mammography, ultrasound, and magnetic resonance imaging features overlap between subtypes, and that ultrasound and MRI are complementary for revealing specific morphological characteristics. No survival or response rates are reported in that imaging study.
A 2017 review of 49 reports involving 53,606 patients with papillary thyroid tumours concludes that the past emphasis on cytologic features to define papillary tumours has not produced ideal pairwise agreement between pathologists and has generated incidence and survival data suggesting overdetection and overdiagnosis. Updated survival analyses demonstrate excellent long-term survival for most patients diagnosed with papillary carcinomas, and the review notes that a reemphasis on diagnostic tissue patterns should improve agreement and reduce incidence.
No controlled trial data exist for any drug in these abstracts. What is missing is prospective trial design, patient stratification by tumour subtype and molecular markers, and funding for studies that test repurposed agents against papillary carcinomas at any site.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Thyroid · 1996 · 23 citations
Papillary Thyroid Carcinoma Metastasizing to the Sphenoid-Ethmoid Sinuses and Skull Base
AbstractMetastatic papillary carcinoma to the sinuses and skull base is a rare occurrence. A case report of aggressive papillary carcinoma is reported. The tumor contained areas of insular and anaplastic degeneration with strong positive staining for p53 oncogene. Management included primary surgery, administration of radioactive iodine, and external beam radiation.
European Journal of Breast Health · 2022 · 11 citations · open access
Digital Mammography, Ultrasound and Magnetic Resonance Imaging Characteristics in Differential Diagnosis of Papillary Carcinoma Subtypes of the Breast and Diagnostic Challenges
AbstractObjective: We aimed to investigate mammography (MG), ultrasound (US), and magnetic resonance imaging (MRI) findings of papillary breast carcinoma subtypes and to compare the diagnostic features and performance of the imaging method in distinguishing subtypes. Materials and Methods: Forty-two patients presenting with pathological diagnosis of 45 papillary carcinoma lesions, between 2014 and 2019, were included. Cases were assigned to five subgroups according to the latest World Health Organization (WHO) classification. The clinical characteristics (n = 45) and imaging features of each pathological subgroup were retrospectively related to imaging findings from US (n = 45), MG (n = 37), and breast MRI (n = 23), and further compared. Results: = 0.017). Conclusion: Radiological findings of papillary carcinomas overlap with each other. US and MRI are complementary when revealing specific morphological characteristics.
American Journal of Clinical Pathology · 2017 · 7 citations · open access
Defining Papillary Carcinoma of the Thyroid
AbstractOBJECTIVES: To review how changes in the pathologic definitions for papillary tumors of the thyroid during recent decades have affected outcomes for patients with these tumors. METHODS: Forty-nine previous reports or studies involving collectively 53,606 patients were reviewed, and new analyses were performed on the data to include analyses of agreement, incidence, survival, and diagnostic categories. RESULTS: The past emphasis on cytologic features to define papillary tumors has not resulted in ideal pairwise agreement between pathologists and has produced incidence and survival data suggesting overdetection and overdiagnosis. Most recently, tissue patterns have been reemphasized. CONCLUSIONS: With the recent reemphasis on diagnostic tissue patterns (over cytologic criteria), agreements between pathologists for the diagnosis of papillary tumors should improve, and the incidence of papillary carcinoma should decline. Nevertheless, updated survival analyses demonstrate excellent long-term survival for most of those diagnosed with papillary carcinomas.
Global Journal of Otolaryngology · 2018 · 0 citations · open access
Laryngeal Papillary Carcinoma in a Developing Community
AbstractLiterature search revealed the rarity of laryngeal papillary carcinoma. A case from Brazil was reported as papillary carcinoma in the headline but as "papillary squamous cell carcinoma" on histopathological study. In the present study, the papillary nature was demonstrated classically.
Global Journal of Otolaryngology · 2018 · 0 citations · open access
AbstractLiterature search revealed the rarity of laryngeal papillary carcinoma.A case from Brazil was reported as papillary carcinoma in the headline but as "papillary squamous cell carcinoma" on histopathological study.In the present study, the papillary nature was demonstrated classically.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
